Publication: The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis
Issued Date
2018-07-01
Resource Type
ISSN
10956859
00908258
00908258
Other identifier(s)
2-s2.0-85044531337
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Gynecologic Oncology. Vol.150, No.1 (2018), 190-200
Suggested Citation
Chuenkamon Charakorn, Kunlawat Thadanipon, Sawarat Chaijindaratana, Sasivimol Rattanasiri, Pawin Numthavaj, Ammarin Thakkinstian The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis. Gynecologic Oncology. Vol.150, No.1 (2018), 190-200. doi:10.1016/j.ygyno.2018.03.056 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46548
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis
Other Contributor(s)
Abstract
© 2018 The Authors Objective: The aim of this systematic review and meta-analysis was to pool association effects of serum squamous cell carcinoma antigen (SCC-Ag) on recurrence and mortality in mainly squamous cell cervical cancer patients. Methods: MEDLINE and Scopus databases were searched up to June 29, 2016. Studies assessing effects of SCC-Ag on recurrence and death in cervical cancer patients were included. Data extraction was independently performed by two reviewers. A meta-analysis was applied for pooling the effects (i.e., risk ratio (RR), hazard ratio (HR), and unstandardized mean difference (USMD)) of SCC-Ag measured before and after treatment on recurrence and death. Results: A total of 61 studies were included. For pretreatment SCC-Ag and recurrence, the pooled RR, HR, and USMD for high versus low serum SCC-Ag were 2.44(95% CI: 1.91, 3.13), 2.23(95% CI: 2.03, 2.45), −7.7(95% CI: -31.7, 16.4), respectively. The corresponding effects for the posttreatment period were 3.91(95% CI: 2.96, 5.16), 3.14(95% CI: 1.29, 7.65), and 3.2(95% CI: -10.6, 17.0), respectively. In addition, patients with high level of pretreatment serum SCC-Ag were also at a higher risk for death than patients with low serum SCC-Ag with a pooled RR of 3.66(95% CI: 2.24, 5.98), pooled HR of 2.50(95% CI: 1.85, 3.37), and pooled USMD of 7.10(95% CI: 4.26, 9.94). The posttreatment serum SCC-Ag effects also reflected a similar trend. Conclusions: The serum SCC-Ag was consistently associated with recurrence and mortality of newly diagnosed cervical cancer. This marker may be useful in monitoring disease progression in cervical cancer patients. Prospero registration number is: CRD42016044024.